Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib

References

• HeidenreichPATrogdonJGKhavjouOAForecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart AssociationCirculation2011123893394421262990
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• SmithSCJrAllenJBlairSNAHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood InstituteCirculation2006113192363237216702489
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trialLancet2002360932672212114036
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFARosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med2008359212195220718997196
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study GroupBaseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)Lancet19953458960127412757746058
   PubMed Web of Science ®Google Scholar
• DavignonJBeneficial cardiovascular pleiotropic effects of statinsCirculation200410923 Suppl 1III394315198965
   PubMed Web of Science ®Google Scholar
• BarterPGottoAMLaRosaJCfor Treating to New Targets InvestigatorsHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsN Engl J Med2007357131301131017898099
   PubMed Web of Science ®Google Scholar
• GordonTCastelliWPHjortlandMCKannelWBDawberTRHigh density lipoprotein as a protective factor against coronary heart disease. The Framingham StudyAm J Med1977625707714193398
   PubMed Web of Science ®Google Scholar
• AssmannGSchulteHvon EckardsteinAHuangYHigh-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transportAtherosclerosis1996124SupplS11208831911
   PubMed Web of Science ®Google Scholar
• GoldbourtUMedalieJHHigh density lipoprotein cholesterol and incidence of coronary heart disease – the Israeli Ischemic Heart Disease StudyAm J Epidemiol19791093296308222135
   PubMed Web of Science ®Google Scholar
• MillerNEThelleDSFordeOHMjosODThe Tromsø heart-studyHigh-density lipoprotein and coronary heart-disease: a prospective case-control studyLancet19771801996596867464
   PubMed Web of Science ®Google Scholar
• GordonDJProbstfieldJLGarrisonRJHigh-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studiesCirculation19897918152642759
   PubMed Web of Science ®Google Scholar
• DuffyDRaderDJEmerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transportCirculation20061131140115016505192
   PubMed Web of Science ®Google Scholar
• ShahPKEmerging HDL-based therapies for atherothrombotic vascular diseaseCurr Treat Options Cardiovasc Med200791607017378977
   PubMedGoogle Scholar
• ClarkRWSutfinTARuggeriRBRaising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapibArterioscler Thromb Vasc Biol200424349049714739125
   PubMed Web of Science ®Google Scholar
• BrousseauMESchaeferEJWolfeMLEffects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterolN Engl J Med20043501505151515071125
   PubMed Web of Science ®Google Scholar
• DavidsonMHMcKenneyJMShearCLRevkinJHEfficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levelsJ Am Coll Cardiol2006481774178117084249
   PubMed Web of Science ®Google Scholar
• McKenneyJMDavidsonMHShearCLRevkinJHEfficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatinJ Am Coll Cardiol2006481782179017084250
   PubMed Web of Science ®Google Scholar
• BarterPJCaulfieldMErikssonMEffects of torcetrapib in patients at high risk for coronary eventsN Engl J Med20073572109212217984165
   PubMed Web of Science ®Google Scholar
• NissenSETardifJCNichollsSJEffect of torcetrapib on the progression of coronary atherosclerosisN Engl J Med20073561304131617387129
   PubMed Web of Science ®Google Scholar
• KasteleinJvan LeuvenSIBurgessLEffect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemiaN Engl J Med20073561620163017387131
   PubMed Web of Science ®Google Scholar
• BotsMLVisserenFLEvansGWTorcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trialLancet2007370958215316017630038
   PubMed Web of Science ®Google Scholar
• KuivenhovenJAde GroothGJKawamuraHEffectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemiaAm J Cardiol2005951085108815842977
   PubMed Web of Science ®Google Scholar
• KrishnaRAndersonMSBergmanAJEffect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studiesLancet200737096031907191418068514
   PubMed Web of Science ®Google Scholar
• ForrestMJBloomfieldDBriscoeRJTorcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosteroneBr J Pharmacol20081541465147318536749
   PubMed Web of Science ®Google Scholar
• VergeerMStroesESThe pharmacology and off-target effects of some cholesterol ester transfer protein inhibitorsAm J Cardiol2009104Suppl32E38E
   PubMed Web of Science ®Google Scholar
• RocheHoffmann-LaA randomized, double-blind, placebo-controlled study assessing the effect of ro4607381 on cardiovascular mortality and morbidity in clinically stable patients with a recent acute coronary syndromeClinicalTrials.gov [Internet]Bethesda, MDNational Library of Medicine2000 [cited May 28, 2012]. Available from: http://clinicaltrials.gov/show/NCT00658515. NLM Identifier: NCT00658515
   Google Scholar
• RanallettaMBieriloKKChenYBiochemical characterization of cholesteryl ester transfer protein inhibitorsJ Lipid Res20105192739275220458119
   PubMed Web of Science ®Google Scholar
• GoedekeLFernández-HernandoCRegulation of cholesterol homeostasisCell Mol Life Sci201269691593022009455
   PubMed Web of Science ®Google Scholar
• BarterPJKasteleinJJTargeting cholesteryl ester transfer protein for the prevention and management of cardiovascular diseaseJ Am Coll Cardiol200647349249916458126
   PubMed Web of Science ®Google Scholar
• ChapmanMJTherapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart diseasePharmacol Ther2006111389390816574234
   PubMed Web of Science ®Google Scholar
• TothPPReverse cholesterol transport: high-density lipoprotein’s magnificent mileCurr Atheroscler Rep2003538639312911849
   PubMedGoogle Scholar
• OliveiraHCde FariaECCholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological rolesIUBMB Life201163424825721488146
   PubMed Web of Science ®Google Scholar
• ShahPKInhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic diseaseEur Heart J200728151217121756
   PubMed Web of Science ®Google Scholar
• ChaitABrazgRLTribbleDLKraussRMSusceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern BAm J Med19939443503568475928
   PubMed Web of Science ®Google Scholar
• KraussRMHeterogeneity of plasma low-density lipoproteins and atherosclerosis riskCurr Opin Lipidol1994553393497858908
   PubMedGoogle Scholar
• HiranoKYamashitaSKugaYAtherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipaseArterioscler Thromb Vasc Biol199515184918567583564
   PubMed Web of Science ®Google Scholar
• ZhongSSharpDSGroveJSIncreased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levelsJ Clin Invest19969712291729238675707
   PubMed Web of Science ®Google Scholar
• RidkerPMParéGParkerANZeeRYMiletichJPChasmanDIPolymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women’s Genome Health StudyCirc Cardiovasc Genet200921263320031564
   PubMedGoogle Scholar
• CurbJDAbbottRDRodriguezBLProspective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderlyJ Lipid Res200445594895314967821
   PubMed Web of Science ®Google Scholar
• TanEYHartmannGChenQPharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeysDrug Metab Dispos20103845947320016052
   PubMed Web of Science ®Google Scholar
• KrishnaRGargAPanebiancoDSingle-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjectsBr J Clin Pharmacol20096853554519843057
   PubMed Web of Science ®Google Scholar
• KrishnaRBergmanAJJinBMultiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjectsClin Pharmacol Ther20088467968318580870
   PubMed Web of Science ®Google Scholar
• KumarSTanEYHartmannGMetabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humansDrug Metab Dispos20103847448320016053
   PubMed Web of Science ®Google Scholar
• DanskyHMBloomfieldDGibbonsPEfficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemiaAm Heart J2011162470871621982664
   PubMed Web of Science ®Google Scholar
• KrishnaRBergmanAJJinBAssessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteersJ Clin Pharmacol2009491808719004846
   PubMed Web of Science ®Google Scholar
• KrishnaRGargAJinBAssessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein(CETP) inhibitor, in healthy subjectsBr J Clin Pharmacol20096752052619552746
   PubMed Web of Science ®Google Scholar
• KrishnaRStypinskiDAliMLack of meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsBr J Clin Pharmacol201274111612422243494
   PubMed Web of Science ®Google Scholar
• KrishnaRStypinskiDAliMLack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjectsBiopharm Drug Dispos201132952552922031172
   PubMed Web of Science ®Google Scholar
• ClarkRWRuggeriRBCunninghamDBambergerMJDescription of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of actionJ Lipid Res200647353755216326978
   PubMed Web of Science ®Google Scholar
• BloomfieldDCarlsonGLSapreAEfficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patientsAm Heart J200915735236019185645
   PubMed Web of Science ®Google Scholar
• KraussRMWojnooskiKOrrJChanges in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapibJ Lipid Res201253354054722180633
   PubMed Web of Science ®Google Scholar
• KrishnaRBergmanAJGreenMDockendorfMFWagnerJADykstraKModel-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitorAAPS J201113217919021347617
   PubMed Web of Science ®Google Scholar
• CannonCPDanskyHMDavidsonMDesign of the DEFINE trial: determining the efficacy and tolerability of CETP inhibition with anacetrapibAm Heart J2009158451351919781408
   PubMed Web of Science ®Google Scholar
• CannonCPShahSDanskyHMDetermining the Efficacy and Tolerability InvestigatorsSafety of anacetrapib in patients with or at high risk for coronary heart diseaseN Engl J Med2010363252406241521082868
   PubMed Web of Science ®Google Scholar
• LandrayMBowmanLREVEAL: Randomized EValuation of the Effects of Anacetrapib through Lipid-modification A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular diseaseClinicalTrials.gov [Internet]Bethesda, MDNational Library of Medicine2000 [cited May 28, 2012]. Available from: http://clinicaltrials.gov/show/NCT01252953. NLM Identifier: NCT01252953
   Google Scholar
• CreiderJCHegeleRAJoyTRNiacin: another look at an underutilized lipid-lowering medicationNat Rev Endocrinol2212012 [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• ZhangLHKamannaVSGanjiSHXiongXMKashyapMLNiacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cellsJ Lipid Res201253594195022389325
   PubMed Web of Science ®Google Scholar
• van der HoornJWde HaanWBerbéeJFNiacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden. CETP miceArterioscler Thromb Vasc Biol200828112016202218669886
   PubMed Web of Science ®Google Scholar
• Abbott LaboratoriesNIASPAN [package insert]North Chicago, ILAbbott Laboratories2010
   Google Scholar
• GilleABodorETAhmedKOffermannsSNicotinic acid: pharmacological effects and mechanisms of actionAnnu Rev Pharmacol Toxicol2008487910617705685
   PubMed Web of Science ®Google Scholar
• BruckertELabreucheJAmarencoPMeta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosisAtherosclerosis2010210235336120079494
   PubMed Web of Science ®Google Scholar
• BodenWEProbstfieldJLAndersonTfor AIM-HIGH InvestigatorsNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255226722085343
   PubMed Web of Science ®Google Scholar
• ChapmanMJRedfernJSMcGovernMEGiralPNiacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular riskPharmacol Ther2010126331434520153365
   PubMed Web of Science ®Google Scholar
• McKeageKKeatingGMFenofibrate: a review of its use in dyslipidaemiaDrugs201171141917194621942979
   PubMed Web of Science ®Google Scholar
• BallantyneCMDavidsonMHPossible differences between fibrates in pharmacokinetic interactions with statinsArch Intern Med2003163192394239514581261
   PubMedGoogle Scholar
• RosensonRSCurrent overview of statin-induced myopathyAm J Med2004116640841615006590
   PubMed Web of Science ®Google Scholar
• GoldbergACBaysHEBallantyneCMEfficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemiaAm J Cardiol2009103451552219195513
   PubMed Web of Science ®Google Scholar
• KhouryNGoldbergACThe use of fibric acid derivatives in cardiovascular preventionCurr Treat Options Cardiovasc Med201113433534221544518
   PubMedGoogle Scholar
• RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study GroupN Engl J Med1999341641041810438259
   PubMed Web of Science ®Google Scholar
• RobinsSJCollinsDWittesJTVA-HIT Study GroupVeterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trialJAMA2001285121585159111268266
   PubMed Web of Science ®Google Scholar
• GinsbergHNElamMBLovatoLCfor ACCORD Study GroupEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010362171563157420228404
   PubMed Web of Science ®Google Scholar
• SanteeJLindseyCPaceHRelative efficacy of antilipemic agents in non-high-density lipoprotein cholesterol reductionJ Pharm Pract522012 [Epub ahead of print.]
   PubMedGoogle Scholar
• MaronDJFazioSLintonMFCurrent perspectives on statinsCirculation2000101220721310637210
   PubMed Web of Science ®Google Scholar